India’s stakes in the Global Pandemic Agreement

The article highlights the tension in global governance between national sovereignty and international solidarity. In the context of the WHO Pandemic Agreement, this tension is most evident in debates over whether global frameworks can set binding targets or mandate sharing of resources like vaccines and technologies. India's approach attempts a delicate balance: supporting international coordination for creating global public goods (like digital infrastructure and equitable vaccine access) while insisting on the primacy of member-states in tailoring policies to their national circumstances. This dynamic is a central theme in UPSC questions regarding multilateral institutions and the balance of power in international relations. The role of World Health Organization in declaring pandemics and its potential infringement on national interests, as cited by the United States, is a key point of analysis for global governance structures.

The core of the WHO Pandemic Agreement negotiations revolves around health equity and addressing the disparities exposed during the COVID-19 pandemic. The Pathogen Access and Benefit-Sharing (PABS) system is critical here; it aims to guarantee that lower-income countries receive a fair share of vaccines and therapeutics. This touches upon the UPSC's focus on global health security and the moral imperative of international cooperation. India, despite being a major vaccine manufacturer ('pharmacy of the world'), relies on global pharmaceuticals for patents and is import-dependent for Active Pharmaceutical Ingredients. Therefore, advocating for a regime that ensures access to technology and resources from the Global North is essential for India's own public health resilience and its leadership role within the Global South.

The economic dimensions of the Pandemic Agreement involve intellectual property rights, technology transfer, and funding mechanisms. The Global South's demand for binding targets on technology transfer and significant funding for initiatives like 'One Health' (monitoring human-animal-environment interfaces) reflects a need for capacity building. Conversely, the Global North's reluctance highlights concerns over intellectual property and financial commitments. For India, the economic strategy involves leveraging its massive domestic health initiatives, such as digital health infrastructure, as 'global public goods' to build influence. Furthermore, ensuring that domestic policies regulating biological materials prioritize equity allows India to credibly demand similar standards globally, linking domestic economic capability with international negotiation strength.